

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 20773

CHEMISTRY REVIEW(S)

Jordan
JUN 4 1998

OFFICE OF NEW DRUG CHEMISTRY/DIVISION OF NEW DRUG CHEMISTRY II

Review of Chemistry, Manufacturing, and Controls

Clinical Review Division: HFD-160 – Division of Medical Imaging and Radiopharmaceutical Drug Products

NDA # **20-773** REVIEW#: 02 REVIEW DATE: June 2, 1998

SUBMISSION TYPE DOCUMENT DATE CDER DATE ASSIGNED DATE

NAME & ADDRESS OF APPLICANT: Bracco Diagnostics, Inc.
Larry Callan P.O.Box 5225
(609) 514 2262 Princeton, NJ 08543-5225


DRUG PRODUCT NAME (Proprietary): SonoRx (Simethicone coated cellulose oral suspension)
NONPROPRIETARY/USAN: Simethicone (0.25%) Coated Cellulose

CODE NAME/#:
CHEM. TYPE/THER. CLASS 3S
PHARMACOL. CATEGORY/INDICATION: Oral enhancing agent for diagnostic ultrasound
DOSAGE FORM: Suspension
STRENGTH(S): 7.5 mg/mL
ROUTE OF ADMINISTRATION: Oral
DISPENSED: Rx
SPECIAL PRODUCTS: Yes No (If yes, fill out the form for special products and deliver to TIA through team leader for data entry)


CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOL.WT:

Cellulose, a polysaccharide with β -linked glucose units, coated with simethicone

Molecular Formula
 $(C_6H_{10}O_5)_n$



Molecular Formula
 $C_6H_{18}OSi_2(C_2H_6OSi)_n$



REMARKS/COMMENTS: The submission responds to the 9/30/97 NA letter, and discussions on the meeting of 11/12/97, relating to the drug substance, drug product, and establishment inspections. All concerns have been addressed in the submission. Labeling for the 400 mL fill size is acceptable, since CMC data for that fill size has been submitted and reviewed. No CMC information has been submitted for the mL size, and it should not be listed on the package insert.

CONCLUSIONS & RECOMMENDATIONS: Reviewer Recommendation: Approval of the 400 mL dosage form, based on resolution of CMC deficiencies identified previously, pending satisfactory inspection results for Westwood Squibb and in specimen dates for these two sites are 5/12/98 and 5/11/98, respectively.

cc:
Orig. NDA 20-773
HFD-160/DivFiles
HFD-161/CSO/RJordan
HFD-160/Chem/DAPlace
HFD-160/ChemTL/ELeutzinger
R/D INIT BY: _____
Filename: 773resub.wpd

FSI 6/4/98

FSI 6/2/98
David A. Place, PhD, Reviewing Chemist

OFFICE OF NEW DRUG CHEMISTRY / DIVISION OF NEW DRUG CHEMISTRY II**Review of Chemistry, Manufacturing, and Controls**




Clinical Review Division: HFD-160 - Division of Medical Imaging and Radiopharmaceutical Drug Products

NDA # **20-773** REVIEW#: **01** REVIEW DATE: 17 Sep 97

SUBMISSION TYPE	DOCUMENT DATE	CDER DATE	ASSIGNED DATE
Original	30 Sep 96	30 Sep 96	15 Sep 96
Minor Amendment	26 Aug 97	28 Aug 97	28 Aug 97

NAME & ADDRESS OF APPLICANT:
 Larry Callan
 (609) 514 2262
 Bracco Diagnostics, Inc.
 P.O.Box 5225
 Princeton, NJ 08543-5225

DRUG PRODUCT NAME (Proprietary): SonoRx (Simethicone coated cellulose oral suspension)
NONPROPRIETARY/USAN: Simethicone (0.25%) Coated Cellulose
CODE NAME/#:
CHEM. TYPE/THER. CLASS 3S
PHARMACOL. CATEGORY/INDICATION: Oral enhancing agent for diagnostic ultrasound
DOSAGE FORM: Suspension
STRENGTH(S): 7.5 mg/mL
ROUTE OF ADMINISTRATION: Oral
DISPENSED: Rx

CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOL.WT:Cellulose, a polysaccharide with β -linked glucose units, coated with simethicone**Molecular Formula****Molecular Formula**SUPPORTING DOCUMENTS: IND DMF

REMARKS/COMMENTS: See Pages of this review for a summary of critical (Non-Approval) and more easily remedied (Approvable) deficiencies, as well as Item H of this review (Lists of Deficiencies and Comments (Draft Letter)).

CONCLUSIONS & RECOMMENDATIONS: Reviewer Recommendation: NON-Approval, based on numerous critical CMC deficiencies.

cc:

Orig. NDA 20-773

HFD-820/Chem/DAPlace

HFD-161/CSO

HFD-160/ChemTL/ELeutzinger

HFD-102/ChemDir Div I Cihhe [#1 ONLY]

R/D INIT BY:

Filename: 20773DP6.vyro

IS/ 9/18/97

IS/ 9/17/97

David A. Place, PhD, Reviewing Chemist